Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

23-11-2022 | ACR 2022 | Conference coverage | Video

SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis (4:49).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

17-11-2022 | ACR 2022 | Conference coverage | News

Secukinumab comparable to adalimumab biosimilar in axSpA

23-07-2020 | Axial spondyloarthritis | News

Secukinumab comparable to TNF inhibition in axSpA

07-11-2020 | ACR 2020 | Conference coverage | News

Secukinumab reduces spinal pain in patients with axSpA

04-10-2021 | Axial spondyloarthritis | News

Inflammation tied to magnitude of secukinumab response in nonradiographic axSpA

Image Credits